Randomized, comparative clinical study of cisplatin and docetaxel combination chemotherapy and mitomycin, vindesine and cisplatin (MVP) combination chemotherapy with concurrent thoracic radiation therapy for locally advanced unresectable non-small-cell lung cancer (OLCSG0007)

INTERVENTION: combination chemotherapy of cisplatin and docetaxel with concurrent thoracic radiation therapy combination chemotherapy of mitomycin, vindesine and cisplatin with concurrent thoracic radiation therapy CONDITION: inoperable locally advanced non‐small‐cell lung cancer PRIMARY OUTCOME: overall survival SECONDARY OUTCOME: response rate; progression‐free survival; pattern of progression/relapse ; adverse events ; treatment compliance INCLUSION CRITERIA: Histologically or cytologically confirmed non‐small‐cell lung cancer No prior therapy Age: 75 years or less Disease stage of unresectable IIIA (bulky N2) or IIIB ECOG performance status of 0 or 1 Measurable lesion(s) Adequate bone marrow function WBC 4,000/cmm or more; PLT 100,000/cmm or more Adequate liver function T Bil 1.5 mg/dl or less; GOT and GPT 2.5 times the upper limit of normal at each institution Adequate kidney function Creatinine 1.5 mg/dl or less; Ccr 60 ml/min or more Adequate pulmonary function Pa02 60 Torr or more However, this will not apply if there is reduced respiratory function due to stenosis of a main bronchus or a lobar bronchus, and it can be expected that resolution of the stenosis will lead to rapid improvement. Acquisition of written informed consent